EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Vynnyk N. I.

    PPAR-γ AGONIST AS PART OF COMBINATION THERAPY IN PATIENTS WITH METABOLIC SYNDROME: ASSESSMENT OF CLINICAL EFFECTIVENESS


    About the author: Vynnyk N. I.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation Recently, much attention is paid to investigation and use of the sensitizer agents. These substances are the ligands for the γ – PPAR-γ peroxisome proliferator-activated receptors. Due to its effect on all components of the metabolic syndrome, glitazones reduce the risk for the development and progression of cardiovascular disease. The paper presents the clinical efficacy of pioglitazonum (PG) in the complex therapy of patients with coronary heart disease (CHD) in combination with metabolic syndrome (MS). It has been proved by evidence that standard therapy, supplemented with PG leads to the increase in labor and physical activity of patients, reduction of subjective pain in the heart, frequency, duration and number of anginous attacks, lowering of the daily amount of nitroglycerin, less complaints of dyspnea and shortness of breath on exertion. This gives the grounds to recommend the PG as a pathogenetically substantiated supplement to the complex therapy of patients with MS in combination with CHD.
    Tags metabolic syndrome, peroxisome proliferator-activated receptor-γ, exertional angina pectoris, ischemic heart disease
    Bibliography
    • Vinnik N. I. Effektivnost primeneniya pioglitazona v kompleksnoy terapii bolnyih ishemicheskoy boleznyu serdtsa na fone metabolicheskogo sindroma / N.I. Vinnik, L.A. Kutsenko, N.L. Kutsenko [i dr.] // Likarska sprava. –Kiyiv «Zdorovya», - 2011. – No. 3-4. – S.67-73.
    • Dudnyk V. M. Otsinka roli transkryptsiinoho faktora nf-kb v mekhanizmakh rozvytku neinfektsiinykh zapalnykh zakhvoriuvan u ditei / V. M. Dudnyk // Mezhdunarodnыi zhurnal pedyatryy, akusherstva y hynekolohyy – 2013. –T. 3 No.1 – S. 75–81.
    • Kaydashev I. P. NF-kB-signalizatsiya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2-go tipa i ateroskleroza / I. P. Kaydashev // Mezhdunarodnyiy endokrinologicheskiy zhurnalyu-2011.- No.3.
    • Kaydashev I. P. Aktivatsiya NF-kB pri metabolichnomu sindromi / I. P. Kaydashev // Fiziologichniy zhurnal. – 2012. – T. 58, No. 1 – S. 93–101.
    • Betteridge D. J. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglytazone / D. J. Betteridge // Fundam Clin Pharmacol. – 2009. – 23 (6). – P. 675–679.
    • Clar C. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis / C. Clar, P. Royle, N. Waugh // Plos ONE. – 2009. – Vol. 4 (7). – P. 102–112.
    • Farias D. R. Metabolic syndrome in coronary artery and occlusive vascular disease: a systematic review / D. R. Farias, A. F. Pereira, G. Rosa // Arg. Bras. Cardiol. – 2010. – Vol. 94 (6). – P. 150–178.
    • Hommelberg P. P. Fatty acidinduced NF-kappaB activation and insulin resistance in skeletal muscle are chain length dependent / P. P. Hommelberg, J. Plat, R. C. Langen [et al.] // - Am. J. Physiol. Endocrinol. Metab. -2009, Vol. 296 (1), P. 114-120.
    • Karin M. NF-kappaB: linking inflammation and immunity to cancer development and progression / M. Karin, F.R. Greten // Nat. Rev. Immunol. –  2005. – Р. 749-759.
    • Kawamori R. Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone – special emphasis on PROactive study and PERISCOPE study / R. Kawamori // Nippon Rinsho. – 2010. – 68 (2). – P. 235–241.
    • Konstantinou D. M. Metabolic syndrome and angiographic coronary artery disease prevalence in association with Framingham risk score / D. M. Konstantinou, Y. S. Chatzizisis, G. E. Louridas [et al.] // Metab Syndr Relat disord. – 2010. – 8 (3). – P. 201–208.
    • Kaul S. Thiazolidinedione drugs and cardiovascular risks. A Science Advisory From the American Heart Association and American College of Cardiology Foundation / S. Kaul, A. F. Bolger, D. Herrington [et al.] // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – P. 1885–1894.
    • Palomer X. The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells. / X. Palomer, D. lvarez-Guardia, M. M. Davidson [et al.] //. PLoS One. – 2011. – Vol. 19724.
    • Qasim A. Adipokines, insulin resistance, and coronary artery disease / A. Qasim, N. N. Mehta, M. G. Tadesse [et al.] // J. Am Coll Cardiol. – 2008. – Vol. 52 (3). – P. 231–236.
    • Santos D. G. Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure / D. G. Santos, M. F. Resende, J. G. Mill [et al.] // BMC Med. Genet. – 2010. – P. 89–26.
    • Thiemermann C. Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size / C. Thiemermann, N. S. Wayman // Med. Sci. Monit. – 2001. – Vol. 7. – P.787–789.
    • Wang J.-X. PPARs: diverse regulators in energy metabolism and metabolic diseases /J.-X. Wang // Cell Research. – 2010. – Vol. 20. – P. 124–137.
    • Ye J. Regulation of PPARγ function by TNF-α / J. Ye // Biochem. Biophys. Res. Commun. – 2008. – Vol. 405-408. 
    Publication of the article «World of Medicine and Biology» №2(60), 2017 year, 017-021 pages, index UDK 616 – 008.9:615